Last reviewed · How we verify
nicotinic acid/laropiprant
nicotinic acid/laropiprant is a Lipid-modifying agent / Antilipemic Small molecule drug developed by Manchester University NHS Foundation Trust. It is currently FDA-approved for Dyslipidemia / mixed dyslipidemia in patients at risk of cardiovascular disease. Also known as: Tredaptive.
Nicotinic acid raises HDL cholesterol and lowers triglycerides and LDL cholesterol, while laropiprant blocks the niacin flush response by antagonizing the GPR109A receptor.
Niacin/laropiprant is being studied for its potential effects on conditions such as coronary heart disease, hypercholesteremia, hyperlipidemia, and hypercholesterolemia. The exact mechanism of action of niacin/laropiprant is not specified, but it is known to be a combination of nicotinic acid and laropiprant, which is a prostaglandin D2 receptor antagonist.
At a glance
| Generic name | nicotinic acid/laropiprant |
|---|---|
| Also known as | Tredaptive |
| Sponsor | Manchester University NHS Foundation Trust |
| Drug class | Lipid-modifying agent / Antilipemic |
| Target | GPR109A receptor (laropiprant component); nicotinic acid acts on multiple lipid metabolism pathways |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Nicotinic acid (niacin) is a B vitamin that activates lipid metabolism pathways to improve the cholesterol profile. Laropiprant is a selective antagonist of the GPR109A receptor, which mediates the uncomfortable flushing side effect caused by nicotinic acid alone, thereby improving tolerability and compliance.
Approved indications
- Dyslipidemia / mixed dyslipidemia in patients at risk of cardiovascular disease
Common side effects
- Flushing (reduced vs. niacin monotherapy)
- Hyperglycemia / elevated glucose
- Hyperuricemia / gout
- Gastrointestinal upset
- Hepatotoxicity
Key clinical trials
- Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133) (PHASE3)
- Lipid Efficacy of the Extended Release Niacin/Laropiprant Combination in Patients With Cardiovascular Disease (PHASE4)
- Effect of Tredaptive on Serum Lipoproteins and Inflammatory Markers (PHASE4)
- A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED) (PHASE1)
- ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART (PHASE4)
- Effect of Nicotinic Acid on Cardiovascular Risks Indices in Polycystic Ovary Syndrome (PHASE4)
- MK-0524B Lipid Study (MK-0524B-063) (PHASE3)
- Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- nicotinic acid/laropiprant CI brief — competitive landscape report
- nicotinic acid/laropiprant updates RSS · CI watch RSS
- Manchester University NHS Foundation Trust portfolio CI
Frequently asked questions about nicotinic acid/laropiprant
What is nicotinic acid/laropiprant?
How does nicotinic acid/laropiprant work?
What is nicotinic acid/laropiprant used for?
Who makes nicotinic acid/laropiprant?
Is nicotinic acid/laropiprant also known as anything else?
What drug class is nicotinic acid/laropiprant in?
What development phase is nicotinic acid/laropiprant in?
What are the side effects of nicotinic acid/laropiprant?
What does nicotinic acid/laropiprant target?
Related
- Drug class: All Lipid-modifying agent / Antilipemic drugs
- Target: All drugs targeting GPR109A receptor (laropiprant component); nicotinic acid acts on multiple lipid metabolism pathways
- Manufacturer: Manchester University NHS Foundation Trust — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Dyslipidemia / mixed dyslipidemia in patients at risk of cardiovascular disease
- Also known as: Tredaptive
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing